Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amifostine in reducing cisplatin toxicity

M Markman1

  • 1The Cleveland Clinic Cancer Center and the Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.

Seminars in Oncology
|October 23, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in Discounting Behavior and Brain Responses for Food and Money Reward.

eNeuro·2024
Same author

Apical hypertrophic cardiomyopathy: A case series at a Brazilian referral center with a maximal follow-up of 15 years.

Annales de cardiologie et d'angeiologie·2021
Same author

Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.

European journal of gynaecological oncology·2018
Same author

Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach.

Current oncology (Toronto, Ont.)·2018
Same author

Surgical intervention in relapsed ovarian cancer is beneficial: contra.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2011

Amifostine can reduce cisplatin toxicity in patients. This protective effect is particularly beneficial for individuals with pre-existing kidney or nerve damage, potentially preventing further harm during cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cisplatin is a widely used chemotherapy agent.
  • Cisplatin can cause significant kidney and neurologic toxicity.
  • Reducing chemotherapy-induced side effects is crucial for patient management.

Purpose of the Study:

  • To evaluate the efficacy of amifostine in mitigating cisplatin-associated toxicity.
  • To assess the protective role of amifostine in patients with compromised renal or neurologic function.

Main Methods:

  • Preclinical evaluations were conducted.
  • A randomized controlled clinical trial was performed.

Main Results:

  • Amifostine demonstrated a reduction in the incidence and severity of cisplatin-induced toxicity in preclinical studies.

Related Experiment Videos

  • Clinical trial results indicated a protective effect of amifostine against cisplatin-related organ damage.

    • Conclusions:

    • Amifostine shows promise in reducing cisplatin-associated toxicities.
    • Patients with pre-existing renal or neurologic dysfunction may benefit from amifostine co-administration to prevent further organ damage.